Third Harmonic Bio, Inc.
THRD
$3.39
-$0.18-5.04%
| Weiss Ratings | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.69 | |||
| Price History | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.25% | |||
| 30-Day Total Return | -2.59% | |||
| 60-Day Total Return | -69.16% | |||
| 90-Day Total Return | -70.48% | |||
| Year to Date Total Return | -69.38% | |||
| 1-Year Total Return | -66.53% | |||
| 2-Year Total Return | -19.14% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -78.93% | |||
| 52-Week Low % Change | 12.26% | |||
| Price | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $16.94 | |||
| 52-Week Low Price | $3.18 | |||
| 52-Week Low Price (Date) | Feb 11, 2025 | |||
| 52-Week High Price (Date) | May 21, 2024 | |||
| Valuation | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 161.02M | |||
| Enterprise Value | -120.83M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.09 | |||
| Earnings Per Share Growth | 40.88% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.56 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.38 | |||
| Enterprise Value/EBITDA (TTM) | 2.05 | |||
| Enterprise Value/EBIT | 2.05 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 44.83M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 209 727 2457 | |||
| Address | 1700 Montgomery Street San Francisco, CA 94111 | |||
| Website | www.thirdharmonicbio.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.86% | |||
| Return on Equity | -- | |||
| Income Statement | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -58.82M | |||
| EBIT (TTM) | -58.87M | |||
| Net Income (TTM) | -45.47M | |||
| Net Income Avl. to Common (TTM) | -45.47M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -91.73% | |||
| EPS Diluted (TTM) | -1.09 | |||
| EPS Diluted Growth (Q YOY) | -70.60% | |||
| Balance Sheet | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 285.06M | |||
| Cash Per Share (Q) | $6.36 | |||
| Total Current Assets (Q) | 290.54M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 285.15M | |||
| Current Ratio (Q) | 40.869 | |||
| Book Value Per Share (Q) | $6.36 | |||
| Total Assets (Q) | 294.61M | |||
| Total Current Liabilities (Q) | 7.11M | |||
| Total Debt (Q) | 3.21M | |||
| Total Liabilities (Q) | 9.46M | |||
| Total Common Equity (Q) | 285.15M | |||
| Cash Flow | THRD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -10.00K | |||
| Cash from Financing (TTM) | 50.51M | |||
| Net Change in Cash (TTM) | 15.99M | |||
| Levered Free Cash Flow (TTM) | -26.19M | |||
| Cash from Operations (TTM) | -34.50M | |||
